Loading…

Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines

Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2024-07, Vol.19 (7), p.e0305930
Main Authors: Wilkinson, Thomas, Garcia-Prats, Anthony J, Sachs, Tina, Paradkar, Mandar, Suryavanshi, Nishi, Kinikar, Aarti, Frias, Melchor V, Sinanovic, Edina, Hesseling, Anneke C, Seddon, James A, Palmer, Megan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing knowledge gap at local and international levels. This normative cost analysis was nested in a Phase I/II pharmacokinetics, safety, tolerability, and acceptability trial of TB medications in children in South Africa, the Philippines and India. It assessed the pharmaceutical costs of 36 childhood RR-TB regimens using combinations from 16 different medicines in 34 oral formulations (adult and child-friendly) in 11 weight bands in children
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0305930